LYRALyra Therapeutics, Inc.

Nasdaq lyratherapeutics.com


$ 0.30 $ -0.01 (-4.8 %)    

Friday, 14-Jun-2024 15:59:55 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 0.2952
$ 0.30
$ 0.00 x 0
$ 0.00 x 0
$ 0.29 - $ 0.30
$ 0.29 - $ 6.79
1,748,930
na
18.9M
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 03-22-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-09-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-09-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-28-2020 03-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lyra-therapeutics-estimates-that-it-will-incur-charges-of-about-39m-41m-in-connection-with-the-workforce-reduction-expects-that-the-majority-of-charges-related-to-workforce-reduction-will-be-incurred-in-q2-of-2024

- SEC Filing

 lyra-therapeutics-implementing-layoff-of-75-of-its-workforce

In the near term, Lyra Therapeutics will focus on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210, a bioabsorbable ...

 hc-wainwright--co-downgrades-lyra-therapeutics-to-neutral-announces-2-price-target

HC Wainwright & Co. analyst Matthew Caufield downgrades Lyra Therapeutics (NASDAQ:LYRA) from Buy to Neutral and announce...

 jefferies-downgrades-lyra-therapeutics-to-hold-lowers-price-target-to-05

Jefferies analyst Dennis Ding downgrades Lyra Therapeutics (NASDAQ:LYRA) from Buy to Hold and lowers the price target from $...

 btig-downgrades-lyra-therapeutics-to-neutral

BTIG analyst Justin Zelin downgrades Lyra Therapeutics (NASDAQ:LYRA) from Buy to Neutral.

 why-lyra-therapeutics-stock-is-down-93-today

Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 t...

 lyra-therapeutics-reports-topline-results-from-phase-3-enlighten-1-trial-for-lyr-210-in-chronic-rhinosinusitis-enlighten-1-trial-did-not-meet-its-primary-endpoint-company-plans-to-evaluate-full-dataset-and-path-forward

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forwardWATERTOWN, Mass., Ma...

 hc-wainwright--co-reiterates-buy-on-lyra-therapeutics-maintains-12-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Buy and maintains $12 pri...